Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size
Trial record 1 of 1 for:    NCT00546351
Previous Study | Return to List | Next Study

Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
UCB Pharma
ClinicalTrials.gov Identifier:
NCT00546351
First received: October 16, 2007
Last updated: September 19, 2014
Last verified: March 2012
History of Changes

October 16, 2007
September 19, 2014
May 2004
January 2011   (final data collection date for primary outcome measure)
  • Number of Participants Experiencing the Occurrence of at Least One Treatment-emergent Adverse Event (TEAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (Approximately 6.5 Years). [ Time Frame: From entry Visit 1 through end of treatment (approximately 6.5 years) ] [ Designated as safety issue: No ]
    Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.
  • Number of Participants Experiencing the Occurrence of at Least One Serious Adverse Event (SAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (Approximately 6.5 Years). [ Time Frame: From entry Visit 1 through end of treatment (approximately 6.5 years) ] [ Designated as safety issue: No ]

    A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:

    • Is fatal
    • Is life-threatening
    • Results in persistent or significant disability/incapacity
    • Requires inpatient hospitalization
    • Prolongs existing inpatient hospitalization
    • Is a congenital anomaly/birth defect
    • Is considered to be an important medical event. Such an event may not be immediately life threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent one of the other outcomes listed in the definitions above
To assess the tolerability and safety of long-term lacosamide administration in subjects with painful distal diabetic neuropathy. Assessment of adverse events, changes in laboratory parameters, ECGs, and physical examinations. [ Time Frame: Assessments are made at all clinic visits. ]
Complete list of historical versions of study NCT00546351 on ClinicalTrials.gov Archive Site
  • Average Daily Pain Score Using an 11-point Likert Scale (0-10) at Baseline Visit. [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    On the Likert Scale, 0 = no pain and 10 = worst possible pain.
  • Average Daily Pain Score Using an 11-point Likert Scale (0-10) at Last Visit. [ Time Frame: Last Visit (approximately 2 years) ] [ Designated as safety issue: No ]
    On the Likert Scale, 0 = no pain and 10 = worst possible pain.
  • Average Pain Score as Measured by a 100 mm Visual Analog Scale (VAS) at Baseline. [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    Visual Analog Scale (VAS) 0 mm = no pain and 100 mm = worst possible pain.
  • Average Pain Score as Measured by a 100 mm Visual Analogue Scale (VAS) at Last Visit. [ Time Frame: Last Visit (approximately 2 years) ] [ Designated as safety issue: No ]
    On VAS 0 mm = no pain and 100 mm = worst possible pain.
  • Patient's Global Impression of Change (PGIC) at Last Visit. [ Time Frame: Last Visit (approximately 2 years) ] [ Designated as safety issue: No ]

    The PGIC is a 7-point self-administered categorical rating scale in which the subject rated the change in pain since starting trial medication (from much worse [score of 1] to much better [score of 7]).

    Reported results are presented as Better (sum of mildly, moderately, or much better), No Change, or Worse (sum of mildly, moderately, or much worse).

  • Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Intensity at Last Visit. [ Time Frame: Baseline Visit; Last Visit (approximately 2 years) ] [ Designated as safety issue: No ]
    0 = no pain and 10 = most intense pain sensation imaginable.
  • Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Sharpness at Last Visit. [ Time Frame: Baseline Visit; Last Visit (approximately 2 years) ] [ Designated as safety issue: No ]
    0 = not sharp and 10 = most sharp sensation imaginable.
  • Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Heat at Last Visit. [ Time Frame: Baseline Visit; Last Visit (approximately 2 years) ] [ Designated as safety issue: No ]
    0 = not hot and 10 = the most hot sensation imaginable.
  • Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Cold at Last Visit. [ Time Frame: Baseline Visit; Last Visit (approximately 2 years) ] [ Designated as safety issue: No ]
    0 = not cold and 10 = the coldest sensation imaginable.
  • Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Dullness at Last Visit. [ Time Frame: Baseline Visit; Last Visit (approximately 2 years) ] [ Designated as safety issue: No ]
    0 = not dull and 10 = most dull sensation imaginable.
  • Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Unpleasantness at Final Visit. [ Time Frame: Baseline Visit; Last Visit (approximately 2 years) ] [ Designated as safety issue: No ]
    0 = not unpleasant and 10 = most unpleasant sensation imaginable.
  • Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Surface Pain at Last Visit. [ Time Frame: Baseline Visit; Last Visit (approximately 2 years) ] [ Designated as safety issue: No ]
    0 = no surface pain and 10 = most intense surface pain imaginable.
  • Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Deep Pain at Last Visit. [ Time Frame: Baseline Visit; Last Visit (approximately 2 years) ] [ Designated as safety issue: No ]
    0 = no deep pain and 10 = most intense deep pain imaginable.
  • Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Itchiness at Final Visit. [ Time Frame: Baseline Visit; Last Visit (approximately 2 years) ] [ Designated as safety issue: No ]
    0 = not itchy and 10 = most itchy sensation imaginable.
  • Within-Subject Change in Neuropathic Pain Using the Neuropathic Pain Scale (NPS) - Sensitivity at Last Visit. [ Time Frame: Baseline Visit; Last Visit (approximately 2 years) ] [ Designated as safety issue: No ]
    0 = not sensitive and 10 = most sensitive sensation imaginable.
  • Average Pain Interference With Sleep (11-point Likert Scale) at Baseline. [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    0 = no interference with sleep and 10 = worst possible interference with sleep.
  • Average Pain Interference With Sleep (11-point Likert Scale) at Last Visit. [ Time Frame: Last Visit ] [ Designated as safety issue: No ]
    0 = no interference with sleep and 10 = worst possible interference with sleep.
  • Average Pain Interference With Activity (11-point Likert Scale) at Baseline. [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    0 = no interference with activity and 10 = worst possible interference with activity.
  • Average Pain Interference With Activity (11-point Likert Scale) at Last Visit. [ Time Frame: Last Visit ] [ Designated as safety issue: No ]
    0 = no interference with activity and 10 = worst possible interference with activity.
  • Average Quality of Life Using the SF-36 Health Survey - Physical Component Summary (PCS) at Baseline. [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.
  • Average Quality of Life Using the SF-36 Health Survey - Physical Component Summary (PCS) at Last Visit. [ Time Frame: Last Visit ] [ Designated as safety issue: No ]
    The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.
  • Average Quality of Life Using the SF-36 Health Survey - Mental Component Summary (MCS) at Baseline. [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.
  • Average Quality of Life Using the SF-36 Health Survey - Mental Component Summary (MCS) at Last Visit. [ Time Frame: Last Visit ] [ Designated as safety issue: No ]
    The SF-36 Health Survey measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS = physical functioning, role-physical, bodily pain, and general health; MCS = vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0 = worst score (or quality of life) and 100 = best score.
The secondary objective is to evaluate the efficacy of long-term use of lacosamide in this indication. Efficacy will be determined by pain score ratings assessed in a patient's diary and with ratings at the clinic visits. [ Time Frame: Efficacy will be determined by pain score ratings assessed in a patient's diary for daily entries and with ratings at the clinic visits. ]
Not Provided
Not Provided
 
Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.
A Multi-center, Open-label, follow-on Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy Including a Double-blind, Randomized Time Point Withdrawal Subtrial.

SP746 (NCT00546351) is a multi-center, open-label, follow-on trial. The purpose of this trial is to assess safety and tolerability of long-term exposure of lacosamide (previously referred to as SPM 927) in subjects with painful distal diabetic neuropathy.
Not Provided
Interventional
Phase 3
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Painful Diabetic Neuropathy
Drug: Lacosamide
50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years
Other Name: Vimpat
Experimental: Lacosamide
50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.
Intervention: Drug: Lacosamide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
621
January 2011
January 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects who completed Study SP743 (NCT00238524) or SP874 (NCT00350103) and, in the investigator's opinion, might benefit from long-term administration of SP746 (NCT00546351). Exception: subjects who prematurely discontinued
  • SP743 (NCT00238524) or SP874 (NCT00350103) due to lack of efficacy or due to intolerability to trial medication (after Visit 5but prior to entering the Maintenance Phase) may be eligible to participate in SP746 (NCT00546351), after consultation with the medical monitor

Exclusion Criteria:

  • Subject has clinically relevant ECG abnormalities, or a QTc interval ≥500 ms, and/or a QTc interval increase of ≥60 ms from the mean pre-dose QTc value at Visit 2 of SP743 (NCT00238524) or SP874 (NCT00350103)
  • Subject has aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≥3 times the upper limit of the normal range (ULN) with total bilirubin ≥2 times ULN or transaminases (AST and/or ALT) ≥5 times ULN
  • Subject has a clinically relevant medical condition that, in the opinion of the investigator, jeopardizes or compromises the subject's ability to participate in this trial
  • Subject is a pregnant or nursing female, or is of childbearing potential and is not surgically sterile, 2 years postmenopausal, or does not practice 2 combined methods of contraception
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Austria,   Belgium,   Bulgaria,   Czech Republic,   Finland,   France,   Germany,   Hungary,   Italy,   Poland,   Romania,   Russian Federation,   Serbia,   Spain,   United Kingdom
Former Serbia and Montenegro
 
NCT00546351
SP0746, 2004-000551-42
No
UCB Pharma
UCB Pharma
Not Provided
Study Director: UCB Clinical Trial Call Center +1 877 822 9493 (UCB)
UCB Pharma
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP